JO3637B1 - مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv - Google Patents

مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Info

Publication number
JO3637B1
JO3637B1 JOP/2016/0080A JOP20160080A JO3637B1 JO 3637 B1 JO3637 B1 JO 3637B1 JO P20160080 A JOP20160080 A JO P20160080A JO 3637 B1 JO3637 B1 JO 3637B1
Authority
JO
Jordan
Prior art keywords
triazolo
pyrazolo
pyrimidine compounds
compounds
rsv antiviral
Prior art date
Application number
JOP/2016/0080A
Other languages
English (en)
Inventor
Jérôme Emile Georges Guillemont
Boris Rogovoy
Pierre Jean-Marie Bernard Raboisson
Antoine Michaut
David Francis Alain Lancois
Anil Koul
Vadim Bichko
Delphine Yvonne Raymonde Lardeau
Dirk André Emmy Roymans
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Application granted granted Critical
Publication of JO3637B1 publication Critical patent/JO3637B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بيرازولو- وترايازولو- بيريميدين مستبدلة مبتكرة لها الصيغة (I) لها نشاط مضاد للفيروسات، بالتحديد، لها نشاط تثبيطي على تكاثر الفيروس المخلوي التنفسي. يتعلق الاختراع ايضا بتركيبات دوائية تشمل هذه المركبات وبمركبات للاستخدام في معالجة عدوي فيروس مخلوي تنفسي.
JOP/2016/0080A 2015-04-28 2016-04-25 مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv JO3637B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153753P 2015-04-28 2015-04-28
US201562204390P 2015-08-12 2015-08-12

Publications (1)

Publication Number Publication Date
JO3637B1 true JO3637B1 (ar) 2020-08-27

Family

ID=55860847

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0080A JO3637B1 (ar) 2015-04-28 2016-04-25 مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Country Status (29)

Country Link
US (3) US10208048B2 (ar)
EP (1) EP3288942B1 (ar)
JP (1) JP6698693B2 (ar)
KR (1) KR102538565B1 (ar)
CN (1) CN107531715B (ar)
AU (1) AU2016254700B2 (ar)
BR (1) BR112017023263B1 (ar)
CA (1) CA2981404C (ar)
CL (1) CL2017002709A1 (ar)
CY (1) CY1125329T1 (ar)
DK (1) DK3288942T3 (ar)
EA (1) EA035689B1 (ar)
ES (1) ES2905550T3 (ar)
HR (1) HRP20211728T1 (ar)
HU (1) HUE057626T2 (ar)
IL (1) IL254750B (ar)
JO (1) JO3637B1 (ar)
LT (1) LT3288942T (ar)
MA (1) MA41974A (ar)
MX (1) MX369040B (ar)
PH (1) PH12017501958B1 (ar)
PL (1) PL3288942T3 (ar)
PT (1) PT3288942T (ar)
SG (1) SG11201708786SA (ar)
SI (1) SI3288942T1 (ar)
TW (1) TWI703146B (ar)
UA (1) UA120448C2 (ar)
WO (1) WO2016174079A1 (ar)
ZA (1) ZA201707320B (ar)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療ｒｓｖ
AU2019216260B2 (en) * 2018-01-31 2023-03-02 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against RSV
ES2957316T3 (es) 2018-04-23 2024-01-17 Janssen Sciences Ireland Unlimited Co Compuestos heteroaromáticos que tienen actividad contra VSR
EP3787617A4 (en) * 2018-05-03 2021-09-08 Georgia State University Research Foundation Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS AND THEIR USES
JP2022507779A (ja) * 2018-11-26 2022-01-18 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｒｓｖに対する活性を有するさらなるヘテロ芳香族化合物
EP3903788A4 (en) 2018-12-27 2022-09-07 Taisho Pharmaceutical Co., Ltd. PYRAZOLO[1,5-A] PYRIMIDINE MACROCYCLIC COMPOUND
CA3136287A1 (en) 2019-05-23 2020-11-26 Guillaume Jean Maurice Mercey Other heteroaromatic compounds having activity against rsv
CN111440173B (zh) * 2020-03-27 2021-05-14 山东大学 一种pi3k抑制剂的制备方法
WO2022020891A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Methods of prophylaxis and treatment of corona virus
WO2022020889A1 (en) * 2020-07-27 2022-02-03 Esfam Biotech Pty Ltd Method of treatment of cytomegalovirus
CN116528850B (zh) 2020-10-28 2025-08-22 盐野义制药株式会社 具有抗病毒活性的酰胺衍生物
CA3207806A1 (en) 2021-02-08 2022-08-11 Dalibor Sames Oxa-ibogaine inspired analogues for treatment of neurological and psychiatric disorders
CN116425754A (zh) * 2021-12-30 2023-07-14 苏州爱科百发生物医药技术有限公司 芳杂双环化合物及其抗病毒用途
EP4540227A2 (en) * 2022-06-17 2025-04-23 Trawsfynydd Therapeutics, Inc. Compounds for treatment a coronavirus infection
WO2024121261A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121262A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121264A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121263A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2026003049A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors
WO2026003043A1 (en) * 2024-06-26 2026-01-02 Janssen Pharmaceutica Nv Malt1 inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ297360A (en) 1994-12-22 2000-03-27 Iaf Biochem Int 5-oxo-5H-thiazolo[3,2-a]pyridine, 5-oxo-2-thia-4a,7-diaza-naphthalene, 4-oxo-octahydro-pyrrolo[1,2-a]pyrazine or 6-oxo-octahydro-pyrido-[2,1-c][1,4]thiazine derivatives and medicaments
AU714072B2 (en) 1995-06-29 1999-12-16 Banyu Pharmaceutical Co., Ltd. Combinations of inhibitors of farnesyl-protein transferase
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5972966A (en) 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
CA2375909A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Tricyclic compounds bearing acyloxymethoxycarbonyl pendants
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2003016274A2 (en) 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
WO2004026225A2 (en) 2002-09-20 2004-04-01 Medisyn Technologies, Inc. Therapeutic agents and corresponding treatments
MXPA05003195A (es) 2002-09-26 2005-06-08 Pfizer Derivados de pirazol como inhibidores de la transcriptasa inversa.
WO2004037817A1 (ja) 2002-10-25 2004-05-06 Mitsubishi Pharma Corporation Ｎ−オキシド化合物
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
WO2005035516A1 (ja) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
JP4537407B2 (ja) 2003-10-30 2010-09-01 ベーリンガー インゲルハイム （カナダ） リミテッド Ｒｓｖポリメラーゼインヒビター
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
KR20060127909A (ko) 2003-12-24 2006-12-13 비오타 사이언티픽 매니지먼트 피티와이 엘티디 호흡기 다핵체 바이러스 감염 치료용 다환 물질
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
CA2612263C (en) * 2005-06-20 2015-04-14 Tibotec Pharmaceuticals Ltd. 1-(2-amino-3-(substituted alkyl)-3h-benzimidazolylmethyl)-3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
JP2009516730A (ja) 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−アラニン誘導体
WO2008011557A2 (en) * 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
MX2011002263A (es) 2008-09-10 2011-05-23 Kalypsys Inc Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades.
TW201022266A (en) 2008-10-23 2010-06-16 Boehringer Ingelheim Int Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR20100101055A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
RS54761B1 (sr) * 2010-06-24 2016-10-31 Gilead Sciences Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
CA2825098C (en) * 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CN106986869A (zh) * 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
AU2015341913B2 (en) 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
ES2704740T3 (es) 2014-12-08 2019-03-19 Janssen Sciences Ireland Uc Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicación del virus sincicial respiratorio (vsr)
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv

Also Published As

Publication number Publication date
EA035689B1 (ru) 2020-07-27
ES2905550T3 (es) 2022-04-11
PH12017501958A1 (en) 2018-03-26
EA201792370A1 (ru) 2018-02-28
TW201708227A (zh) 2017-03-01
CA2981404C (en) 2023-09-19
KR102538565B1 (ko) 2023-05-30
CN107531715A (zh) 2018-01-02
WO2016174079A1 (en) 2016-11-03
US10208048B2 (en) 2019-02-19
SG11201708786SA (en) 2017-11-29
BR112017023263A2 (pt) 2018-08-07
HRP20211728T1 (hr) 2022-02-18
KR20170139122A (ko) 2017-12-18
SI3288942T1 (sl) 2022-01-31
MX369040B (es) 2019-10-25
US20180105529A1 (en) 2018-04-19
IL254750A0 (en) 2017-11-30
CA2981404A1 (en) 2016-11-03
EP3288942A1 (en) 2018-03-07
EP3288942B1 (en) 2021-10-27
US10611769B2 (en) 2020-04-07
BR112017023263B1 (pt) 2023-04-11
UA120448C2 (uk) 2019-12-10
JP6698693B2 (ja) 2020-05-27
US20190248793A1 (en) 2019-08-15
AU2016254700B2 (en) 2020-01-02
DK3288942T3 (da) 2022-01-17
MA41974A (fr) 2018-03-07
CL2017002709A1 (es) 2018-04-20
CN107531715B (zh) 2021-03-30
HK1248230A1 (zh) 2018-10-12
AU2016254700A1 (en) 2017-10-19
US11084826B2 (en) 2021-08-10
HUE057626T2 (hu) 2022-05-28
MX2017013884A (es) 2018-03-16
TWI703146B (zh) 2020-09-01
PH12017501958B1 (en) 2018-03-26
US20200223855A1 (en) 2020-07-16
PL3288942T3 (pl) 2022-02-21
JP2018514544A (ja) 2018-06-07
IL254750B (en) 2020-07-30
CY1125329T1 (el) 2024-02-16
PT3288942T (pt) 2021-12-17
ZA201707320B (en) 2020-08-26
LT3288942T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
PH12017501958A1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
MX2017007429A (es) Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
PH12017501534A1 (en) Antiviral compounds
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12015500355B1 (en) Compounds for the treatment of paramoxyvirus viral infections
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
MX2021002168A (es) Compuestos antivirales.
MX381994B (es) Inhibidor de janus quinasa.
PH12018501962B1 (en) Stablizied soluble pre-fusion rsv f proteins
NZ725399A (en) Macrocylic pyrimidine derivatives
PH12020550673A1 (en) Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv)
PH12017500558A1 (en) 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
MX2021014301A (es) Otros compuestos heteroaromaticos que tienen actividad contra el vrs.
MX2020011200A (es) Compuestos heteroaromaticos que tienen actividad contra vrs.
MX2020008061A (es) Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs.
MX2021006138A (es) Otros compuestos heteroaromaticos que tienen actividad contra el vrs.
MX2017007430A (es) Derivados triciclicos de pirazolo [1,5-a]pirimidina sustituidos con piperidina con actividad inhibidora en la replicacion del virus sincitial respiratorio (vsr).
AU2014298561A8 (en) Substituted pyridine-piperazinyl analogues as RSV antiviral compounds
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.